Kazuoki Kondo, MD
Tanabe Pharma Corporation · Mitsubihsi Tanabe Pharma Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kazuoki Kondo, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:29 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT02622113 · Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02354235 · Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)Tanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02314637 · Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic PatientsTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph1NCT02307643 · Exploratory Study of MT-1303 in Systemic Lupus Erythematosus PatientsTanabe Pharma Corporation · completed · Systemic Lupus Erythematosus · study director
- Ph4NCT02227849 · Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02220907 · Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph4NCT02220920 · Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph1NCT02148185 · Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's DiseaseTanabe Pharma Corporation · completed · Crohn's Disease · study director
- Ph4NCT02081599 · Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01680159 · A Clinical Study of Increased Dose of TA-650 in Patients With PsoriasisTanabe Pharma Corporation · completed · Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized) · study director
- Ph3NCT01585155 · Clinical Study of TA-650 in Pediatric Patients With Ulcerative ColitisTanabe Pharma Corporation · completed · Pediatric Ulcerative Colitis · study director
- Ph3NCT01580670 · Clinical Study of TA-650 in Pediatric Patients With Crohn's DiseaseTanabe Pharma Corporation · completed · Pediatric Crohn's Disease · study director
- Ph3NCT01532570 · Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special LesionsTanabe Pharma Corporation · completed · Behcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease · study director
- Ph1NCT01512849 · A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01468584 · Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsTanabe Pharma Corporation · completed · Chronic Hepatitis C · study director
- Ph3NCT01466192 · Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsTanabe Pharma Corporation · completed · Chronic Hepatitis C · study director
- Ph3NCT01301833 · Long-term Safety Study of MP-513 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01072331 · Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes MellitusTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01026194 · Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00998881 · Monotherapy Study of MP-513 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00974090 · Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph1/Ph2NCT00707954 · Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic PatientsTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00628212 · Efficacy and Safety Study of MP-513 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes · study director
- Ph2NCT00497198 · Efficacy and Safety Study of MCI-196 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.